Literature DB >> 22358883

Oral administration of antigen does not influence the proliferation and IFN-γ production of responsive CD8+ T cells but enables to establish T cell clones with different lymphokine production profile.

K Nishijima, T Hisatsune, H Kato, M Kohyama, M Kakehi, S Hachimura, S Kaminogawa.   

Abstract

Feeding of a whole casein diet, which abolished the α(s1)-casein-specific proliferation and IFN-γ productivity of CD(4+) T cells, did not affect the proliferative response of CD8(+) T cells with regard to the antigen dose response, cell dose response, kinetics of the proliferation and epitope specificity, as well as IFN-γ production. To assess the characteristics of the CD8(+) T cells, we established α(s1)-casein-specific CD8(+) T cell clones from both casein-fed and control mice. The established clones produced different amount of IFN-γ and IL-10, and one clone derived from the casein-fed mice produced a remarkable amount of IL-10. The clones from casein-fed mice produced considerable amounts of TGF-β, while those from control mice produced only small amounts. The possible role of CD8(+) T cells in oral tolerance is discussed.

Entities:  

Year:  1997        PMID: 22358883      PMCID: PMC3466738          DOI: 10.1023/A:1007907732222

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  52 in total

1.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.

Authors:  K Falk; O Rötzschke; S Stevanović; G Jung; H G Rammensee
Journal:  Nature       Date:  1991-05-23       Impact factor: 49.962

2.  Engineered secreted T-cell receptor alpha beta heterodimers.

Authors:  C Grégoire; N Rebaï; F Schweisguth; A Necker; G Mazza; N Auphan; A Millward; A M Schmitt-Verhulst; B Malissen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

3.  Antibodies raised against peptide fragments of bovine alpha s1-casein cross-react with the intact protein only when the peptides contain both B and T cell determinants.

Authors:  A Enomoto; D H Shon; Y Aoki; K Yamauchi; S Kaminogawa
Journal:  Mol Immunol       Date:  1990-06       Impact factor: 4.407

4.  Antibodies raised against peptide fragments of bovine alpha s1-casein cross-react with the native protein, but recognize sites distinct from the determinants on the protein.

Authors:  D H Shon; A Enomoto; K Yamauchi; S Kaminogawa
Journal:  Eur J Immunol       Date:  1991-06       Impact factor: 5.532

5.  A suppressive lymphokine derived from Ts clone 13G2 is IL-10.

Authors:  T Hisatsune; Y Minai; K Nishisima; A Enomoto; K W Moore; T Yokota; K Arai; S Kaminogawa
Journal:  Lymphokine Cytokine Res       Date:  1992-04

6.  Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin.

Authors:  D Melamed; A Friedman
Journal:  Eur J Immunol       Date:  1993-04       Impact factor: 5.532

Review 7.  The molecular cell biology of interferon-gamma and its receptor.

Authors:  M A Farrar; R D Schreiber
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

8.  Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells.

Authors:  Y Chen; J Inobe; V K Kuchroo; J L Baron; C A Janeway; H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

9.  Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease.

Authors:  M M Shull; I Ormsby; A B Kier; S Pawlowski; R J Diebold; M Yin; R Allen; C Sidman; G Proetzel; D Calvin
Journal:  Nature       Date:  1992-10-22       Impact factor: 49.962

Review 10.  Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens.

Authors:  H L Weiner; A Friedman; A Miller; S J Khoury; A al-Sabbagh; L Santos; M Sayegh; R B Nussenblatt; D E Trentham; D A Hafler
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.